Brief episodes of sublethal hypoxia reprogram brain response to face possible subsequent lethal stimuli by triggering adaptive and prosurvival events—a phenomenon denominated hypoxic preconditioning (HP). To date, the potential therapeutic implications of HP to forestall sporadic Alzheimer's disease (sAD) pathology remain unexplored. Using a well-established protocol of HP and focusing on hippocampus as a first brain region affected in AD, this study was undertaken to investigate the potential protective effects of HP in a sAD rat model induced by the intracerebroventricular (icv) administration of streptozotocin (STZ) and to uncover the mitochondrial adaptations underlying this nonpharmacological strategy.
Results:
HP prevented the memory and learning deficits as well as tau pathology in the icvSTZ rat model. HP also attenuated icvSTZ-related reactive astrogliosis, as noted by increased glial fibrillary acidic protein immunoreactivity and myo-inositol levels. Notably, HP abrogated the icvSTZ-related impaired energy metabolism and oxidative damage. Particularly, HP averted increased lactate, glutamate, and succinate levels, and decreased mitochondrial respiratory chain function and mitochondrial DNA content. Concerning mitochondrial adaptations underlying HP-triggered tolerance to icvSTZ, preconditioned hippocampal mitochondria displayed an enhanced complex II-energized mitochondrial respiration, which resulted from a coordinated interaction between mitochondrial biogenesis and fusion–fission. Mitochondrial biogenesis was stimulated immediately after HP, whereas in a latter phase mitochondrial fusion–fission events are modulated favoring the generation of elongated mitochondria.
Innovation and Conclusion:
Overall, these results demonstrate for the first time that HP prevents the sAD-like phenotype, in part, by targeting mitochondria emerging as a preventive strategy in the context of AD. Antioxid. Redox Signal. 37, 739–757.
Get full access to this article
View all access options for this article.
References
1.
2020 Alzheimer's disease facts and figures. Alzheimers Dement 2020. [Epub ahead of print]; DOI: 10.1002/alz.12068.
2.
ArnoldSE, ArvanitakisZ, Macauley-RambachSL, KoenigAM, WangHY, AhimaRS, CraftS, GandyS, BuettnerC, StoeckelLE, HoltzmanDM, and NathanDM. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol, 14: 168–181, 2018.
3.
ArranzAM and De StrooperB. The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications. Lancet Neurol, 18: 406–414, 2019.
4.
BarbierP, ZejneliO, MartinhoM, LasorsaA, BelleV, Smet-NoccaC, TsvetkovPO, DevredF, and LandrieuI. Role of tau as a microtubule-associated protein: structural and functional aspects. Front Aging Neurosci, 11: 204, 2019.
5.
BarjaG.Mitochondrial oxygen radical generation and leak: sites of production in states 4 and 3, organ specificity, and relation to aging and longevity. J Bioenerg Biomembr, 31: 347–366, 1999.
6.
BernardoTC, BelezaJ, Rizo-RocaD, Santos-AlvesE, LealC, MartinsMJ, AscensaoA, and MagalhaesJ. Physical exercise mitigates behavioral impairments in a rat model of sporadic Alzheimer's disease. Behav Brain Res, 379: 112358, 2020.
7.
BoenglerK, LochnitG, and SchulzR. Mitochondria “THE” target of myocardial conditioning. Am J Physiol Heart Circ Physiol, 315: H1215–H1231, 2018.
8.
BraskieMN and ThompsonPM. Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings. Trends Cogn Sci, 17: 510–516, 2013.
9.
BrautiganDL, Ferguson-MillerS, and MargoliashE. Mitochondrial cytochrome c: preparation and activity of native and chemically modified cytochromes c. Methods Enzymol, 53: 128–164, 1978.
10.
CardosoS, CarvalhoC, CorreiaSC, SeicaRM, and MoreiraPI. Alzheimer's Disease: from mitochondrial perturbations to mitochondrial medicine. Brain Pathol, 26: 632–647, 2016.
11.
CardosoS, SeicaR, and MoreiraPI. Diabesity and brain energy metabolism: the case of Alzheimer's disease. Adv Neurobiol, 19: 117–150, 2017.
12.
ChenCY, SunWZ, KangKH, ChouHC, TsaoPN, HsiehWS, and FuWM. Hypoxic preconditioning suppresses glial activation and neuroinflammation in neonatal brain insults. Mediat Inflamm, 2015: 632592, 2015.
13.
ChengZY, HuYH, XiaQP, WangC, and HeL. DRD1 agonist A-68930 improves mitochondrial dysfunction and cognitive deficits in a streptozotocin-induced mouse model. Brain Res Bull, 2021: 175, 136–149.
14.
ChetelatG, DesgrangesB, de la SayetteV, ViaderF, EustacheF, and BaronJC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology, 60: 1374–1377, 2003.
15.
CollaboratorsGBDD.Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol, 18: 88–106, 2019.
16.
CooreHG, DentonRM, MartinBR, and RandlePJ. Regulation of adipose tissue pyruvate dehydrogenase by insulin and other hormones. Biochem J, 125: 115–127, 1971.
17.
CorreiaS, CarvalhoC, SantosMS, ProencaT, NunesE, DuarteAI, MonteiroP, SeicaR, OliveiraCR, and MoreiraPI. Metformin protects the brain against the oxidative imbalance promoted by type 2 diabetes. Med Chem, 4: 358–364, 2008.
18.
CorreiaSC, CardosoS, SantosRX, CarvalhoC, SantosMS, PerryG, SmithMA, and MoreiraPI. New insights into the mechanisms of mitochondrial preconditioning-triggered neuroprotection. Curr Pharm Des, 17: 3381–3389, 2011.
19.
CorreiaSC, SantosRX, CardosoSM, SantosMS, OliveiraCR, and MoreiraPI. Cyanide preconditioning protects brain endothelial and NT2 neuron-like cells against glucotoxicity: role of mitochondrial reactive oxygen species and HIF-1alpha. Neurobiol Dis, 45: 206–218, 2012.
20.
CorreiaSC, SantosRX, PerryG, ZhuX, MoreiraPI, and SmithMA. Mitochondria: the missing link between preconditioning and neuroprotection. J Alzheimers Dis, 20 Suppl 2: S475–S485, 2010.
21.
CorreiaSC, SantosRX, PerryG, ZhuX, MoreiraPI, and SmithMA. Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease?. Ageing Res Rev, 10: 264–273, 2011.
22.
CorreiaSC, SantosRX, SantosMS, CasadesusG, LamannaJC, PerryG, SmithMA, and MoreiraPI. Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer's disease. Curr Alzheimer Res, 10: 406–419, 2013.
23.
CrisostomoL, JarakI, RatoLP, RaposoJF, BatterhamRL, OliveiraPF, and AlvesMG. Inheritable testicular metabolic memory of high-fat diet causes transgenerational sperm defects in mice. Sci Rep, 11: 9444, 2021.
24.
DengY, LiB, LiuY, IqbalK, Grundke-IqbalI, and GongCX. Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: implication for Alzheimer's disease. Am J Pathol, 175: 2089–2098, 2009.
25.
DuboisB, HampelH, FeldmanHH, ScheltensP, AisenP, AndrieuS, BakardjianH, BenaliH, BertramL, BlennowK, BroichK, CavedoE, CrutchS, DartiguesJF, DuyckaertsC, EpelbaumS, FrisoniGB, GauthierS, GenthonR, GouwAA, HabertMO, HoltzmanDM, KivipeltoM, ListaS, MolinuevoJL, O'BryantSE, RabinoviciGD, RoweC, SallowayS, SchneiderLS, SperlingR, TeichmannM, CarrilloMC, CummingsJ, and JackCRJr. Proceedings of the Meeting of the International Working G, the American Alzheimer's Association on “The Preclinical State of AD, July, Washington Dc USA. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement, 12: 292–323, 2016.
26.
EllmanGL, CourtneyKD, AndresVJr., and Feather-StoneRM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol, 7: 88–95, 1961.
27.
FukeS, Kubota-SakashitaM, KasaharaT, ShigeyoshiY, and KatoT. Regional variation in mitochondrial DNA copy number in mouse brain. Biochim Biophys Acta, 1807: 270–274, 2011.
28.
GratuzeM, Joly-AmadoA, VieauD, BueeL, and BlumD. Mutual relationship between tau and central insulin signalling: consequences for AD and tauopathies?. Neuroendocrinology, 107: 181–195, 2018.
29.
GreenLC, Ruiz de LuzuriagaK, WagnerDA, RandW, IstfanN, YoungVR, and TannenbaumSR. Nitrate biosynthesis in man. Proc Natl Acad Sci U S A, 78: 7764–7768, 1981.
30.
GriebP.Intracerebroventricular Streptozotocin Injections as a Model of Alzheimer's Disease: in search of a relevant mechanism. Mol Neurobiol, 53: 1741–1752, 2016.
31.
GrunblattE, Salkovic-PetrisicM, OsmanovicJ, RiedererP, and HoyerS. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem, 101: 757–770, 2007.
32.
GutsaevaDR, CarrawayMS, SulimanHB, DemchenkoIT, ShitaraH, YonekawaH, and PiantadosiCA. Transient hypoxia stimulates mitochondrial biogenesis in brain subcortex by a neuronal nitric oxide synthase-dependent mechanism. J Neurosci, 28: 2015–2024, 2008.
33.
HaamJ and YakelJL. Cholinergic modulation of the hippocampal region and memory function. J Neurochem, 142 Suppl 2: 111–121, 2017.
34.
JasovaM, KancirovaI, WaczulikovaI, and FerkoM. Mitochondria as a target of cardioprotection in models of preconditioning. J Bioenerg Biomembr, 49: 357–368, 2017.
35.
JungME, SimpkinsJW, WilsonAM, DowneyHF, and MalletRT. Intermittent hypoxia conditioning prevents behavioral deficit and brain oxidative stress in ethanol-withdrawn rats. J Appl Physiol (1985), 105: 510–517, 2008.
36.
LinAM, ChenCF, and HoLT. Neuroprotective effect of intermittent hypoxia on iron-induced oxidative injury in rat brain. Exp Neurol, 176: 328–335, 2002.
37.
MishraP and ChanDC. Metabolic regulation of mitochondrial dynamics. J Cell Biol, 212: 379–387, 2016.
38.
MoloneyAM, GriffinRJ, TimmonsS, O'ConnorR, RavidR, and O'NeillC. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging, 31: 224–243, 2010.
39.
MoreiraPI, SantosMS, MorenoA, and OliveiraC. Amyloid beta-peptide promotes permeability transition pore in brain mitochondria. Biosci Rep, 21: 789–800, 2001.
40.
MoritaM, Ikeshima-KataokaH, KreftM, VardjanN, ZorecR, and NodaM. Metabolic plasticity of astrocytes and aging of the brain. Int J Mol Sci, 20: 941, 2019.
41.
MorrisR.Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods, 11: 47–60, 1984.
42.
MosconiL, MisturR, SwitalskiR, TsuiWH, GlodzikL, LiY, PirragliaE, De SantiS, ReisbergB, WisniewskiT, and de LeonMJ. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging, 36: 811–822, 2009.
43.
OnyangoIG, LuJ, RodovaM, LeziE, CrafterAB, and SwerdlowRH. Regulation of neuron mitochondrial biogenesis and relevance to brain health. Biochim Biophys Acta, 1802: 228–234, 2010.
44.
OteraH and MiharaK. Mitochondrial dynamics: functional link with apoptosis. Int J Cell Biol, 2012: 821676, 2012.
45.
PeknyM, WilhelmssonU, TatlisumakT, and PeknaM. Astrocyte activation and reactive gliosis-A new target in stroke?. Neurosci Lett, 689: 45–55, 2019.
46.
Perez-PinzonMA.Neuroprotective effects of ischemic preconditioning in brain mitochondria following cerebral ischemia. J Bioenerg Biomembr, 36: 323–327, 2004.
47.
PinhoTS, VerdeDM, CorreiaSC, CardosoSM, and MoreiraPI. O-GlcNAcylation and neuronal energy status: implications for Alzheimer's disease. Ageing Res Rev, 46: 32–41, 2018.
48.
PrinczA, KounakisK, and TavernarakisN. Mitochondrial contributions to neuronal development and function. Biol Chem, 399: 723–739, 2018.
49.
RatoL, AlvesMG, DiasTR, LopesG, CavacoJE, SocorroS, and OliveiraPF. High-energy diets may induce a pre-diabetic state altering testicular glycolytic metabolic profile and male reproductive parameters. Andrology, 1: 495–504, 2013.
50.
Rodriguez-ArellanoJJ, ParpuraV, ZorecR, and VerkhratskyA. Astrocytes in physiological aging and Alzheimer's disease. Neuroscience, 323: 170–182, 2016.
51.
RybnikovaE and SamoilovM. Current insights into the molecular mechanisms of hypoxic pre- and postconditioning using hypobaric hypoxia. Front Neurosci, 9: 388, 2015.
52.
RybnikovaE, VataevaL, TyulkovaE, GluschenkoT, OtellinV, Pelto-HuikkoM, and SamoilovMO. Mild hypoxia preconditioning prevents impairment of passive avoidance learning and suppression of brain NGFI-A expression induced by severe hypoxia. Behav Brain Res, 160: 107–114, 2005.
53.
RyuWI, BormannMK, ShenM, KimD, ForesterB, ParkY, SoJ, SeoH, SonntagKC, and CohenBM. Brain cells derived from Alzheimer's disease patients have multiple specific innate abnormalities in energy metabolism. Mol Psychiatry, 26: 5702–5714, 2021.
54.
Salkovic-PetrisicM, Osmanovic-BarilarJ, BrucknerMK, HoyerS, ArendtT, and RiedererP. Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study. J Neural Transm (Vienna), 118: 765–772, 2011.
55.
SchetingerMR, BonanCD, FrassettoSS, WyseAT, SchierholtRC, WebberA, DiasRD, SarkisJJ, and NettoCA. Pre-conditioning to global cerebral ischemia changes hippocampal acetylcholinesterase in the rat. Biochem Mol Biol Int, 47: 473–478, 1999.
56.
ShaoG, ZhangR, WangZL, GaoCY, HuoX, and LuGW. Hypoxic preconditioning improves spatial cognitive ability in mice. Neurosignals, 15: 314–321, 2006.
57.
SilvaAM and OliveiraPJ. Evaluation of respiration with clark-type electrode in isolated mitochondria and permeabilized animal cells. Methods Mol Biol, 1782: 7–29, 2018.
58.
SkulachevVP.Mitochondrial filaments and clusters as intracellular power-transmitting cables. Trends Biochem Sci, 26: 23–29, 2001.
59.
ThomasLW and AshcroftM. Exploring the molecular interface between hypoxia-inducible factor signalling and mitochondria. Cell Mol Life Sci, 76: 1759–1777, 2019.
60.
Thushara VijayakumarN, SangwanA, SharmaB, MajidA, and RajanikantGK. Cerebral Ischemic Preconditioning: the road so far. Mol Neurobiol, 53: 2579–2593, 2016.
61.
TolarM, AbushakraS, and SabbaghM. The path forward in Alzheimer's disease therapeutics: reevaluating the amyloid cascade hypothesis. Alzheimers Dement, 16: 1553–1560, 2020.
62.
TonderaD, GrandemangeS, JourdainA, KarbowskiM, MattenbergerY, HerzigS, Da CruzS, ClercP, RaschkeI, MerkwirthC, EhsesS, KrauseF, ChanDC, AlexanderC, BauerC, YouleR, LangerT, and MartinouJC. SLP-2 is required for stress-induced mitochondrial hyperfusion. EMBO J, 28: 1589–1600, 2009.
63.
TotaS, KamatPK, ShuklaR, and NathC. Improvement of brain energy metabolism and cholinergic functions contributes to the beneficial effects of silibinin against streptozotocin induced memory impairment. Behav Brain Res, 221: 207–215, 2011.
64.
van der KantR, GoldsteinLSB, and OssenkoppeleR. Amyloid-beta-independent regulators of tau pathology in Alzheimer disease. Nat Rev Neurosci, 21: 21–35, 2020.
65.
WangCH, ChangA, TsaiMJ, ChengH, LiaoLP, and LinAM. Kainic acid-induced oxidative injury is attenuated by hypoxic preconditioning. Ann N Y Acad Sci, 1042: 314–324, 2005.
66.
WellerJ and BudsonA. Current understanding of Alzheimer's disease diagnosis and treatment. F1000Res 7: F1000 Faculty Re, v-1161, 2018.
67.
XuYF, ZhangYJ, ZhangAH, ZhangQ, WuT, and WangJZ. Attenuation of okadaic acid-induced hyperphosphorylation of cytoskeletal proteins by heat preconditioning and its possible underlying mechanisms. Cell Stress Chaperones, 9: 304–312, 2004.
68.
YiannopoulouKG, AnastasiouAI, ZachariouV, and PelidouSH. Reasons for failed trials of disease-modifying treatments for Alzheimer disease and their contribution in recent research. Biomedicines, 7: 97, 2019.
69.
ZhangHX, DuGH, and ZhangJT. Ischemic pre-conditioning preserves brain mitochondrial functions during the middle cerebral artery occlusion in rat. Neurol Res, 25: 471–476, 2003.
70.
ZhuLL, ZhaoT, LiHS, ZhaoH, WuLY, DingAS, FanWH, and FanM. Neurogenesis in the adult rat brain after intermittent hypoxia. Brain Res, 1055: 1–6, 2005.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
